EmailHospital Circular 05/2007
Date Issued: 26 March 2007
Distribution: Public Hospitals
Subject: Highly Specialised Drugs Program
Purpose: To advise hospitals of changes to the Highly Specialised Drugs Program, effective 1 April 2007.
We have had recent advice from the Commonwealth Government of changes to the Highly Specialised Drugs Program, effective 1 April 2007.
Deleted Items
Amprenavir |
||||
| 6334J | Oral solution 15mg/ml, 240ml | 1 | Agenerase | GK |
| 6333H | Capsule 150mg | 240 | Agenerase | GK |
Items discontinued by the manufacturer.
Price Increase
Lamivudine |
|||||
| 6257H | Tablet 100mg | 28 | $149.36 | Zeffix | GK |
| 6271C | Oral solution, 5mg/ml, 240ml | 1 | $64.01 | Zeffix | GK |
Amended Restrictions
Adefovir Dipivoxil |
||
| 6450L | Hepsera | GI |
| Full prescribing criteria for all items available at the Commonwealth/State Highly Specialised Drugs Program Guidelines website. | ||
Pegfilgrastim |
||
| 6363X | Neulasta | AN |
| Full prescribing criteria for all items available at the Commonwealth/State Highly Specialised Drugs Program Guidelines website. | ||
Peginterferon Alfa-2b |
||
| 6441K, 6412L, 6413M, 6414N & 6415P | PEG-Intron Redipen | SH |
| Full prescribing criteria for all items available at the Commonwealth/State Highly Specialised Drugs Program Guidelines website. | ||
Changes notified by hospital circular will be updated in the Guidelines on the Commonwealth/State Highly Specialised Drugs Program Guidelines website and the claim form amended.
Dr Jennifer King
Director, Programs
Metropolitan Health & Aged Care Services
